Press release SurgiMAb – investisseurs

SurgiMab > News & Events > News > SurgiMab receives 1 Million € from its investors to bring its first product to the clinic > Press release SurgiMAb – investisseurs

18 April 2016 Administrateur SurgiMabLeave a comment0

Press release SurgiMAb - investisseurs

9 février 2012 SurgiMAb entreprise de biotechnologie spécialisée dans le développement de conjugués fluorescents pour l’aide à la chirurgie en oncologie annonce avoir reçu 1 Million d’Euros de ses investisseurs Abalis Finance et Cathey World Investments Ltd pour porter son premier produit jusqu’aux phases de développement clinique.

Previous Post
SurgiMab receives 1 Million € from its investors to bring its first product to the clinic

About SurgiMab

SurgiMAb develops injectable fluorescent conjugates to be used during Fluorescence-Guided Surgery (FGS) by oncology surgeons so they can clearly delineate tumors and visualize infra-clinical size nodules invisible to their naked eyes.

Latest news

SurgiMab will sponsor the next edition of the International Symposium on Fluorescence Guided Surgery, 2-3 Nov 2023 in Amsterdam
SurgiMab will participate to the conference “Optics in the Life Sciences” during the Optica Biophotonics Congress in Vancouver April 23 – 27, 2023

Home . Legal & credits